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Paclitaxel-containing aminoester phosphate 4 and phosphoamidate 9 were synthesised and found to possess anticancer activity
against HL-60 leukemia cells; their solubility in a phosphate buffer solution was about 16 times higher than that of paclitaxel. 
Paclitaxel 1 is one of the most promising anticancer agents;1 it
inhibits cell division and other interphase processes by stabilising
microtubules.2–6 This anticancer agent has an extremely low
solubility in water.4,5 Thus, enormous efforts have been focused
on the modification of paclitaxel in order to create more water-
soluble and, consequently, more easily formulated and delivered
drugs.7 
New paclitaxel derivatives could be designed to convert, in a
predictable fashion, into the original active drug by either an
enzymic mechanism8–12 or simple hydrolysis initiated under
physiological pH conditions.13 Most accounts to date for pacli-
taxel 1 have been concerned with its esterifications at the
C-2' 7,11,14–21 or C-711,22–25 hydroxyl group for improvement
of the water solubility while the cytotoxic activity is main-
tained.7,14–19,21–23,25
In general, dephosphorylation occurs easier in cancer cells
than in normal cells. Thus, chemotherapeutic agents possessing
a phosphate or phosphoamidate unit would preferentially interact
with the cancer cells.26 Given these phenomena, we designed
and synthesised new paclitaxel-containing aminoester phosphate
4 (Scheme 1) and phosphoamidate 9 (Scheme 2)27 with higher
water solubility. These new propaclitaxel analogues were found
to possess anti-leukemic activity slightly greater than that of
paclitaxel.
To synthesise 2'-[4-(N,N-dimethylammonium)butyryl]paclitaxel
7-phosphate 4, we condensed paclitaxel 1 with 4-(N,N-di-
methylamino)butyric acid 2 in the presence of dicyclohexyl-
carbodiimide (DCC) and a catalytic amount of (dimethyl-
amino)pyridine (DMAP) in CH2Cl2 at 25 °C (Scheme 1).† Cor-
responding amino ester 3 was obtained in 88% yield. The
reaction of 3 with P(OMe)Cl2 in the presence of collidine in
THF at 0 °C and then with I2 and water at 25 °C produced the
target compound, ammonium ester phosphate 4, in 90% yield.27
Compound 4 existed in its zwitterionic form.
For the preparation of 2'-[3-(phosphoamido)propionyl]pacli-
taxel 9, we treated paclitaxel 1 with 3-(N-monomethoxytrityl-
amino)propionic acid 6 in the presence of DCC and DMAP in
CH2Cl2 at 25 °C to give monomethoxytritylated amino ester 7
in 95% yield (Scheme 2).‡ Compound 7 in wet acetonitrile was
treated with a catalytic amount of ceric ammonium nitrate
(CAN) at 25 °C to afford detritylated amino ester 8 in 97%
yield.28 The reaction of 8 with P(OMe)Cl2 and collidine in THF
and then with I2 and water produced desired phosphoamidate 9
in 85% yield.27
† The structure of compound 3 was confirmed by the 1H NMR (CDCl3,
300 MHz) spectrum, which showed characteristic peaks at d 2.17 (s, 6H,
2NMe) and 5.50 (d, 1H, 2'-H, J 3.2 Hz). Compound 4 showed charac-
teristic peaks in 1H NMR (CDCl3, 300 MHz) d: 5.07 (dd, 1H, 7-H, J
10.7, 6.4 Hz) and 7.11 (br. d, 1H, NH). 
‡ The structure of compound 7 was confirmed by the 1H NMR (CDCl3,
300 MHz) spectrum, which showed characteristic peaks at d 3.75 (s, 3H,
OMe) and 5.68 (d, 1H, 2'-H, J 7.1 Hz). Compound 8 showed a
characteristic peak in 1H NMR (CDCl3, 300 MHz) d: 3.14 (br. s, 2H,
NH2). Compound 9 showed a characteristic peak in 1H NMR (CDCl3,
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The solubility (µmol dm–3) in a phosphate buffer solution
(0.10 M, pH 6.5) was 896 for 4, 952 for 9 and 57.8 for
paclitaxel 1. Paclitaxel-containing aminoester phosphate 4 and
phosphoamidate 9 were tested in vitro against HL-60 leukemic
cells.29,30 The IC50 values (µmol dm–3) were 4.0×10–3 for 4,
3.8×10–3 for 9 and 4.5×10–3 for 1.
In comparison with paclitaxel 1, new compounds 4 and
9 were found ~16 times more soluble in a phosphate buffer
solution, and they exhibited comparable anti-leukemic activities
in vitro. The free C(2')–OH group is essential for the anticancer
activity of paclitaxel.27 Therefore, hydrolysis of the ester com-
ponent in 4 and 9 under physiological pH conditions to give 5
and 1, respectively, is responsible for the anti-leukemic activity
of these new paclitaxel derivatives. On the other hand, the C(7)-
phosphate functionality in 5 cannot be hydrolysed in vitro where
phosphoesterases are not present. Thus, the C(7)-phosphate
derivative of paclitaxel (i.e., 5) possesses anti-leukemic activity
comparable with that of paclitaxel 1.
This work was supported by the National Health Research
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